TRANSLATE

The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

mds logo
Brought to you by Scientific Education Support
View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more
Editorial theme │ Understanding the new classification and stratification systems in MDS: IPSS-R and IPSS-M

Editorial theme │ Understanding the new classification and stratification systems in MDS: IPSS-R and IPSS-M

Here, we summarize the key points comparing the IPSS-M and IPSS-R stratification systems in MDS, including their pros and cons from experts’ perspectives, and results from a validation study of the IPSS-M.

Dec 22, 2023| 5 min

"How I treat” based on the new/updated classification systems

"How I treat” based on the new/updated classification systems

During the MDS Hub Steering Committee meeting, held on October 26, 2023, Pierre Fenaux chaired ...

Dec 14, 2023

“How I treat” a patient with lower-risk MDS showing signs of ESA failure

“How I treat” a patient with lower-risk MDS showing signs of ESA failure

During the MDS Hub Steering Committee meeting, held on October 26, 2023, Theo de Witte chaired ...

Dec 14, 2023

Expert recommendations for clinical trial design to facilitate drug development in MDS

Expert recommendations for clinical trial design to facilitate drug development in MDS

A panel of MDS experts convened by the U.S. FDA provided recommendations for improving clinical...

Dec 13, 2023| 2 min

Theo de Witte
Theo de Witte

"The MDS Hub allows you to access the most relevant updates in myelodysplastic syndromes and related disorders. We aim to deliver valuable and up-to-date information and expert opinions to all physicians practicing hemato-oncology."

Featured Expert Opinion

What do data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?

What do data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?

The AML Hub was pleased to speak to Uwe Platzbecker, University of Leipzig Medical Center, Leip...

Oct 20, 2023

Most read

International Consensus Classification of MDS: 2022 updates

International Consensus Classification of MDS: 2022 updates

We summarize the key points from the new ICC of myeloid neoplasms, in particular referring to M...

Mar 31, 2023| 5 min

Editorial theme │ Understanding MDS classification and stratification systems: WHO and ICC

Editorial theme │ Understanding MDS classification and stratification systems: WHO and ICC

Here, we summarize the key points comparing classification systems in MDS—WHO and ICC—focusing ...

Nov 13, 2023| 6 min

Imetelstat in patients with lower-risk MDS: Updates from the IMerge trial

Imetelstat in patients with lower-risk MDS: Updates from the IMerge trial

At ASCO 2023 and EHA 2023, updates were presented on the efficacy and safety of imetelstat, inc...

Jul 11, 2023| 6 min

Revised International Working Group 2023 response criteria for higher-risk MDS

Revised International Working Group 2023 response criteria for higher-risk MDS

We summarize the recently published revised International Working Group response criteria for h...

Apr 19, 2023| 4 min|Higher-risk

MDS-related mutations

VIEW ALL
Editorial theme │ Understanding the new classification and stratification systems in MDS: IPSS-R and IPSS-M

Editorial theme │ Understanding the new classification and stratification systems in MDS: IPSS-R and IPSS-M

Here, we summarize the key points comparing the IPSS-M and IPSS-R stratification systems in MDS...

Dec 22, 2023| 5 min

Editorial theme │ Understanding MDS classification and stratification systems: WHO and ICC

Editorial theme │ Understanding MDS classification and stratification systems: WHO and ICC

Here, we summarize the key points comparing classification systems in MDS—WHO and ICC—focusing ...

Nov 13, 2023| 6 min

Allo-HSCT in patients with high-risk MDS: Analysis from the BMT CTN 1102 trial

Allo-HSCT in patients with high-risk MDS: Analysis from the BMT CTN 1102 trial

We summarize a genetic analysis from the BMT CTN 1102 trial that assessed the impact of the pre...

Nov 7, 2023| 2 min

Ivosidenib granted FDA approval for the treatment of patients with R/R IDH1-mutated MDS

Ivosidenib granted FDA approval for the treatment of patients with R/R IDH1-mutated MDS

On October 24, 2023, the U.S. FDA approved ivosidenib, an IDH1 inhibitor, for the treatment of ...

Oct 25, 2023| 1 min

EBMT 2023

VIEW ALL
EBMT 2023

EBMT 2023

Catch up with our live Twitter coverage from the EBMT Meeting, 2023.

Apr 24, 2023